Alkem Laboratories and Biosergen AB have embarked on a significant partnership, solidified through a co-development and license agreement. This strategic alliance is aimed at jointly advancing the development and subsequent commercialization of Biosergen’s groundbreaking polyene macrolide antifungal product, known as BS005.
In the realm of financial markets, on Monday, Alkem’s shares experienced a marginal decline of 0.16% at the National Stock Exchange (NSE), closing at a price of Rs. 3,545. This underscores the ongoing developments and investor sentiment surrounding this collaboration.